Library / Laws / 117th Congress / Senate Bills / S. 1428
S. 1428
To prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable companies to delay the entry of biosimilar biological products and interchangeable biological products.
| Print stage | Date | Size | ⠃ |
|---|---|---|---|
| Introduced in Senate | 2021-04-28 | 20.3K | ⠃⠗⠋ |
| Reported in Senate | 2021-04-28 | 43.5K | ⠃⠗⠋ |